
Today’s post is a round-up of recent eSubmission-related news from the agencies, based on posts from my twitter account, www.twitter.com/kathie_clark. Next time, a roundup of articles and conferences.
The regulatory authorities haven’t put out much in the way of major updates recently, but there have been some updates worth noting:
The individual agencies in Europe have also issued some updates:
As I discussed in my previous post, FDA issued version 1.5.1 of Study Data Specifications in January of 2010. Although the changes in the new version were not great, they were significant for eCTD as a new specification for organizing datasets was defined. The change has to do with how the files are organized in the file structure in which an eCTD is delivered to indicate whether they were STDM or legacy format. However, the change had no effect on the Table of Contents that is visible to a reviewer (created from the eCTD XML backbone). In a recent development, ICH M2 working group has defined an update to the valid values list for study tagging files to introduce file tags that would allow a review tool to identify dataset types when displaying the eCTD Table of Contents.
The new specifications for organizing study datasets and their associated files in folders are summarized in the following figure. In the document, an accompanying table provides further definition of the folders.
New Dataset Folder Organization
Compare this with the folder structure required in the previous specification:
Previous Dataset Folder Organization
You will see an important difference: tabulations must be assigned to a folder based on whether they are STDM datasets or legacy format. A second difference is that there is now a separate folder for datasets under analysis, where previously analysis datasets were placed directly in the analysis folder.
At the recent ICH meeting in Estonia, the valid-values.xml that defines file tags used to identify the documents in studies was amended to better support the different types of data:
Look for the new valid-values.xml on the ICH websites in a zip file. You should talk with your publishing vendor to find out how and when they will support the updated specification.
One final note – the FDA recently retired their own version of the valid-values.xml and reverted to the ICH version. That means that they restored the file tag of nonclinical-data. However, the preferred file tag for a nonclinical study is pre-clinical-study-report.
A few months ago, FDA issued version 1.5.1 of Study Data Specifications. Although the changes in the new version were not great, they were significant for eCTD as a new specification for organizing datasets was defined. The change has to do with how the files are organized in the file structure in which an eCTD is delivered and has no effect on the Table of Contents that is visible to a reviewer (created from the eCTD XML backbone).
The specifications for organizing study datasets and their associated files in folders are summarized in the following figure. No additional subfolders are needed; unused folders do not need to be supplied. In the document, an accompanying table provides further definition of the folders.
The problem that this is causing in the short term is that current publishing tools are not set up to produce this structure. Looking at the folder structure required in the previous specification:
You will see an important difference: tabulations must be assigned to a folder based on whether they are STDM datasets or legacy format. The problem is that most publishing tools don’t “know” which of the formats are being used, and aren’t prepared to create and populate the legacy and sdtm folders.
A second difference is that there is now a separate folder for datasets under analysis, where previously analysis datasets were placed directly in the analysis folder.
So where does that leave sponsors? I see three main options:
I would be interested in hearing about what approach people are taking.
As most people who work with eCTD are aware, agencies will accept clinical study reports structured in one of two ways:
There are advantages and disadvantages to each, which are outside the scope of this posting (you can request GlobalSubmit’s white paper “What Makes an eCTD Clinical Study Easily Reviewed by the FDA?” if you are interested in more detail). And in fact, thorough our work with the FDA, GlobalSubmit has found that some clients take a “hybrid” approach and submit a legacy report along with other files. Whatever approach is taken, the study, through the mechanism of the study tagging file, must be constructed so that each component is properly tagged and identified.
In a recent gathering with representatives from a number of Pharma companies, the question was raised (mainly regarding US submissions) as to which of the two formats sponsors were using.
The companies who have been submitting eCTD for some time appear to have made the switch to the granular/E3 format for the most part. However, they had different ways of meeting the review and approval challenges that are brought on when you no longer have a single document (or set of paper binders) to approve:
Sponsors need to understand how clinical reviewers will be seeing the studies they submit. You can see some FDA presentations on this subject on GlobalSubmit’s Agency Presentations page. Sponsors can also contact us to learn more about the FDA’s eCTD viewer, which is a GlobalSubmit product.
As promised, here is an expanded list of posts published recently on my twitter account, this time related to agency news:
There has been a lot going on at the various European agencies in the last few months. This week, we look at some of the announcments and guidance that has been issued across Europe recently.
France: - Caroline AURICHE, Philippe DÜRR and Cécile LEVY from AFSSAPS spoke at EXL Pharma, presenting on Taking the plunge from paper into electronic-only in the EU - the 18-month feed-back experience of «paperlessland» in the French Health Products Safety Agency. AFSSAPS details include:
Germany: The Federal Institute for Drugs and Medical Devices (BfArM) announced that it will accept pure electronic filings (eCTD or NeeS) from mid-February 2010 (previously a full paper copy was required). Only those documents requiring signature will be required in papert.
The BfArM will soon add a section on “electronic filing” to its homepage (www.bfarm.de) to consolidate information The BfArM will be making further announcements closer to the date
Austria: In news passed on from Tim Feldgate of Applied Regulatory Consulting’s blog article Electronic submission available for human use, the AGES PharmMed now accepts, but does not require, purely electronic submissions for human use without additional paper copy, except for those documents that need to be signed: Company letter and application form. eCTD is the preferred standard, and it is the default Nees is only a temporary solution.
Belgium: Federal Agency for Medicines and Health Products advises on automatic emails sent after eSubs uploaded in their system and passed or failed compliance requirements
Belgium: New version of the Belgian agency’s NeeS checker tool: see the agency’s e-Submissions page (you must navigate to the Human Use tab and then the eSubmissions link) (translated from the Dutch) for the file checker and associated documents.
Spain: AEMPS has issued a new version of their NeeS guidance ENVÍO POR PARTE DE LOS LABORATORIOS DE INFORMACIÓN EN FORMATO ELECTRÓNICO A LA AEMPS on December 22nd (in Spanish only.
UK: in The Medicines (Products for Human Use) (Amendments to Fees for Variations) Regulations 2009 , eCTD fees were set at a lower level than other submission types.
UK: E-SUBMISSIONS - Frequently Asked Questions (FAQ) for Vet Meds in the UK has been updated to clarify that the root folder of a Vet Meds eSubmission is part of the submission, and that following the naming conventions for files and folders (with regards to forbidden characters) is important – your submission may be rejected even for use of upper case.
Turkey: Turkish eSubs guidance (in Turkish) has been issued. per Andrew Marr “This is essentially NeeS but with specific file and folder naming in Turkish, with CTD section numbers too. I believe that the final guidance will allow Modules 4 and 5 to use the English folder and filenames.”
Cyprus: the Ministry of Health has issued GUIDANCE FOR PROVIDING REGULATORY INFORMATION IN ELECTRONIC FORMAT SUBMISSIONS. They will accept electronic submissions within the National Procedure, the Mutual Recognition Procedure and the Decentralised Procedure in eCTD or NeeS format. However, the Cover Letter and the Application Form must be submitted in paper with an original signature. The guidance provides information on disk and file formats, packaging and labeling, electronic signature, validation, etc. “The Pharmaceutical Services, Ministry of Health have a strong preference for the submission of electronic regulatory information and sees clear benefits for both regulators and industry.”
Greece: the National Organization for Medicines has posted Instructions for Filing Electronically (translated from the Greek by Google). Human products still require M1-M3 in paper but discourage paper for modules 4 and 5. Vet meds and labeling requirements are also discussed.
Norway: Statens legemiddelverk announced acceptance of / strong recommendation for electronic submissions 1 Jan 2010 (translated from Norwegian by Google).
Sweden: in updates to their Electronic submissions page, MPA prefers “as far as possible be able to work solely with electronic submissions for all medical products.” From the 1st January 2010 the MPA will also accept electronic submissions in NeeS or VNtA formats for veterinary medical products within all procedures.
Bulgaria: the Bulgarian authority has issued an announcement that from 01.01.2010 all types of procedures must be in electronic format -eCTD or NeeS - for all procedure types in Bulgaria (translated by Google). They specify which documents are still required in paper in addition. There is also a Guide for electronic submission of documents eCTD and Nees (this was issued last March). For a more detailed discussion of Bulgaria and eSubmissions, see ForeignExchange Translations blog entry Bulgaria catches up with e-Submissions.
Poland: the Polish agency has announced the acceptance of electronic submissions from 1 January 2010 (Nees, eCTD), with the proviso that certain specified documents must be submitted in paper form, regardless of their submission in electronic form.
P.S. I had previously announced all of this news on Twitter, albeit in abbreviated form. Be sure to follow me on Twitter for timely updates - go to www.twitter.com/kathie_clark to follow me.
The ICH M2 ESTRI Main Page has been updated with the following announcement:
“ICH M2 has initiated the development of the Next Major Version of the eCTD (eCTD NMV) to improve robustness, flexibility and long term stability of the message. In accordance with the decision by the ICH Steering Committee that technical specifications should no longer be developed solely within ICH, but should be created in collaboration with Standards Development Organisations (SDOs), the eCTD NMV will be developed jointly with the HL7 RPS project. M2 has developed this list of requirements as input into the HL7 RPS Project.”
I took a look at the requirements (which have been posted before in various drafts). They stretch to nine pages, and range from some that are uncontroversial and obvious to some that signal a significant change in direction. In this posting, I point out some of the more interesting requirements.
Regulatory Activities
The new spec really supports the concept of organizing sequences into regulatory activities. A regulatory activity is a collection of sequences that lead to a decision by the regulatory agency (such as an MAA, Variation, NDS, SNDS, Original NDA, Supplement, etc.) which can be mapped to individual ICH-regional regulatory processes. This concept does not exist in ICH eCTD, although the regional authorities have added it using the concept of “related sequence.” The NMV spec includes a number of formal requirements to support the Regulatory Activity concept.
Cross Application References
Current eCTD does not support cross application references, but neither does it prohibit their use. The only authority to my knowledge who actively supports them is the FDA (who will send you a document providing directions if you email them at esub@fda.hhs.gov ). EMEA expressly forbids them.
The new spec explicitly supports them as shown in the following requirements:
Future of Study Tagging Files (STFs)
When I first read the requirement
When the same documentation is provided, it should be submitted in the same way across HAs. For example, when a study report is submitted in US it is submitted using the STF which is not acceptable in other HAs. This minimizes reuse capabilities and adds to Industry costs to prepare globally harmonized dossiers.
I wasn’t sure if ICH was suggesting that the STF concept should go away altogether. I asked my colleague Jason Rock, who represents the FDA at ICH M2. Jason explained that the goal was to do away with the STF as a separate XML file. STF information would be contained in the main backbone, and could be ignored by authorities who don’t want it. This was also confirmed in a later requirement reading “STF construct should be integrated into the message standard.”
Maintenance of Metadata:
Many sponsors have experienced problems with their eCTD due to the inability of the standard to accommodate corrections or changes in metadata (such as manufacturer). eCTD NMV requirements include the requirement for the message to support the addition, updating and deletion of metadata to a previously submitted instances, e.g., related sequences, submission type, operation attribute, manufacturer name, etc.
Lifecycle
New NMV requirements regarding lifecycle are likely to be applauded by sponsors:
Physical File Rules
The days of relying on a standard folder structure for XML-based eSubmissions are coming to an end as all parties move to acknowledge that they should be using the backbone/TOC and not the file system. The NMV spec includes a requirement that “The physical file structure. (file/folder structure) should be minimal”.
File names would also be able to include underscores, which will come as a relief to anyone who has struggled with if or how to eliminate underscores from SAS file names.
Logical Groupings
New mechanisms for grouping files at levels below sections are called for:
Scope
An important architectural concept for eCTD NMV/RPS is the separation of the messaging mechanism from the TOC. The TOC is no longer built into the specification, but supplied by the regional authorities. This is encapsulated in the requirement “Allow the capacity to modify the ICH CTD organizational structure (ToC) without modifying or changing the eCTD message structure.”
Compatibility
For those worried about the impact of the switch on their current eCTDs, some compatibility requirements should provide some reassurance:
***This just in: our first session is completely full, and we have added a second session on December 8th, 11 am EST (a time more friendly to our European colleagues):
http://www.eventbrite.com/event/474671756
_______________________________________________________________
Don’t have time to keep up-to-date on eCTD regulations and guidance around the world? Wondering when eCTD will become mandatory, (or even accepted), in a given market? Join GlobalSubmit and Cato Research on Thursday, November 5th at 2:00 PM EST for a free educational webinar titled, eCTD Regulations and Status Worldwide.
I’ll be the main presenter, and I’ll review the status of eCTD in the US, Europe, Canada, Japan, Australia and Switzerland. I will also provide you with a convenient list of references and contacts.
At the end of the session’s Q&A, a CATO representative will give a brief overview of the latest happenings in the CRO realm and answer any questions you may have.
Date: November 5, 2009
Time: 2:00 PM EST
Please note: this event is designed for sponsors, and is open only to users registering with a valid email address from a pharmaceutical domain (no gmail, yahoo, etc. accounts).
To Register: Click here or paste this URL into your browser: http://www.eventbrite.com/event/471856335
As promised, the EMEA released Version 1.4 of the EU Module 1 Specification on schedule in August. The new spec has some changes that will impact eCTD assembly, publishing, verification and viewing software tools. The EMEA has reached out to the vendor community to ensure that they are aware of the changes to ensure that they can modify their products in advance of the required implementation timeline. It’s worth reproducing that timeline here – quoting from EU Module 1 Implementation Guidance:
1. Applicants are advised that, from 1st January 2010, when the new variation regulation comes into force, the EU M1 v1.4 must be used for any eCTD submission for any European procedure that contains grouped variations or is subject to a worksharing agreement. Grouped variation or worksharing eCTD submissions provided from this date using any previous version of the EU M1 specification (v1.0. v1.1, v1.2.1 or v1.3) will not be accepted. All European Regulatory Authorities must therefore be able to accept eCTD submissions built using EU M1 v1.4 from 1st January 2010.
2. Applicants are further advised that, from 1st July 2010, the EU M1 v1.4 must be used for all eCTD submissions for all European procedures, and any eCTD submissions provided from this date using any previous version of the EU M1 specification (v1.0. v1.1, v1.2.1 or v1.3) will not be accepted
The nature of this timeline is related to the most significant change in V1.4: the Specification and DTD have been amended so as to support the New Variations Regulation. The envelope has been reviewed so as to support the different modes of submission for variations: single, grouping and worksharing.
A new envelope element, submission ‘mode’ is now provided for use with variations and line extensions. A related change involves the use of a “high-level” submission number for worksharing submissions and certain grouped submissions. Submission publishing tools will require user interface changes to accommodate these requirements, and publishers will need to be aware of their correct usage. EMEA has also provided a number of sample submissions to illustrate the correct use of these elements.
Another significant change is a new limit on folder path length. The Specification has been amended to update the maximum length for file path. The new maximum length has been set to 180 characters. That is, the overall folder and file name path length starting from the sequence number should not exceed 180 characters, for any file in any module. This is an EU regional requirement, and it is acknowledged that this is less than the ICH agreed overall path length. This may cause issues for anyone using attribute-related folder paths (such as drug substance, indication, etc.) of more than a dozen characters or so. Although this won’t affect sequences already submitted, it will mean that some sponsors may have to modify their conventions in this area (keep in mind that the HAs have said that folder names do not have to actually match metadata in the eCTD backbone).
A few more minor changes:
· The ATC number metadata in M1 has been retired
· A few new values have been added for submission type
· A new stylesheet has been supplied
· Naming conventions for the tracking table have been updated
Sponsors need to prepare to accept and validate updated versions of their publishing tools and will need to work with vendors to ensure that updates will be available in advance of the portion of the deadline that applies to them based on their submission plans. They will also need to update some procedures.
It’s worth reviewing the EU Module 1 V1.4 Release Notes to make sure you understand all the changes…
In other EMEA news, a The NeeS validation criteria v1.0 (a set of technical validation criteria to be applied to all non-eCTD electronic submissions has been drafted. Finally, Practical guidelines on the use of the eCTD format for the Plasma Master File (PMF), for the submission of MAAs for plasma derived medicinal products and medical devices that include a PMF certificate, and for 2nd step procedures, has been released by EMEA.